<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html dir="ltr" xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml">
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- 
	This website is powered by TYPO3 - inspiring people to share!
	TYPO3 is a free open source Content Management Framework initially created by Kasper Skaarhoj and licensed under GNU/GPL.
	TYPO3 is copyright 1998-2015 of Kasper Skaarhoj. Extensions are copyright of their respective owners.
	Information and contribution at http://typo3.org/
-->



<title>INHN: Samuel Gershon: Device for naltrexone delivery</title>
<meta name="generator" content="TYPO3 4.5 CMS" />

<link rel="stylesheet" type="text/css" href="IMAGES/STYLESHEET_9B1E31873F2366.CSS?1645000983" media="all" />



<script src="IMAGES/JAVASCRIPT_93077BB238F3E1.JS?1645000982" type="text/javascript"></script>


<link href="IMAGES/LAYOUT_3COL_STANDARD.CSS" rel="stylesheet" type="text/css" /><!--[if lte IE 7]><link href="fileadmin/styles/patches/../01_layouts_basics/css/patches/patch_3col_standard.css" rel="stylesheet" type="text/css" /><![endif]-->
<meta name="DC.title" content="Samuel Gershon: Device for naltrexone delivery" />
<meta name="description" content="INHN" />
<meta name="DC.Description" content="INHN" />
<meta name="keywords" content="International Network for the History of Neuropsychopharmacology" />
<meta name="DC.Subject" content="International Network for the History of Neuropsychopharmacology" />
<meta name="copyright" content="Copyright INHN 2012-14" />
<meta name="DC.Rights" content="Copyright INHN 2012-14" />
<meta http-equiv="content-language" content="en" />
<meta name="DC.Language" scheme="NISOZ39.50" content="en" />
<link rev="made" href="mailto:inhn@inhn.org" />
<meta http-equiv="reply-to" content="inhn@inhn.org" />
<meta name="author" content="Gregers Wegener" />
<meta name="DC.Creator" content="Gregers Wegener" />
<meta name="rating" content="General" />
<meta name="date" content="2019-10-15T22:39:16+00:00" />
<meta name="DC.date" content="2019-10-15T22:39:16+00:00" />
<meta name="robots" content="index,follow" />
<meta name="revisit-after" content="7" />
<link rel="start" href="INDEX681A.HTM?id=1" />
<link rel="up" href="INDEXAF9F.HTM?id=355" />
<link rel="next" href="INDEX8E42.HTM?id=3064" />
<link rel="prev" href="INDEX031F.HTM?id=3472" />
<link rel="canonical" href="INDEXCD60.HTM?id=3191" />



</head>
<body id="pageUID-3191">


<div id="page_margins">
	<div id="page">
		<div id="header"><div class="tx-macinasearchbox-pi1">
		
<form action="https://inhn.org/index.php?id=5&amp;L=0" method="post" name="searchform" id="searchform">
<input name="tx_indexedsearch[sword]" type="text" value="Enter search word..." onclick="this.value=''" onblur="this.value='Enter search word...'" /><br />
<input type="hidden" name="tx_indexedsearch[_sections]" value="0" />
<input type="hidden" name="tx_indexedsearch[pointer]" value="0" />
<input type="hidden" name="tx_indexedsearch[ext]" value="0" />
<input type="hidden" name="tx_indexedsearch[lang]" value="0" />
</form>

	</div>
	<div id="topnav"><a class="skip" href="#navigation" title="Direkt zur Navigation springen">Zur Navigation springen</a><span class="hideme">.</span><a class="skip" href="#content" title="Direkt zum Content springen">Zum Content springen</a><span class="hideme">.</span><a href="INDEX3A9F.HTM?id=6" target="_self">Sitemap</a>&nbsp;&#124;&nbsp;<a href="INDEXD61C.HTM?id=5" target="_self">Search</a>&nbsp;&#124;&nbsp;<a href="INDEX65E4.HTM?id=kontakt" target="_self">Contact</a>&nbsp;&#124;&nbsp;<a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a></div><a href="INDEX2999.HTM?id=202"><img class="headImg1" src="IMAGES/COMPANY_LOGO.GIF" alt="" title="Home" width="598" height="100" /></a></div>
		<div id="nav"><a id="navigation" name="navigation"></a><div id="nav_main" class="hlist"><ul><li><a href="INDEX2999.HTM?id=202" target="_self"><span>Home</span></a></li><li><a href="INDEX7EFD.HTM?id=479" target="_self"><span>Dictionary</span></a></li><li><a href="INDEX3E5C.HTM?id=374" target="_self"><span>Drugs</span></a></li><li><a href="INDEXDBB1.HTM?id=565" target="_self"><span>Photos</span></a></li><li><a href="INDEXD919.HTM?id=342" target="_self"><span>Profiles</span></a></li><li id="current"><a href="INDEXAF9F.HTM?id=355" target="_self"><span>Controversies</span></a></li><li><a href="INDEXD122.HTM?id=641" target="_self"><span>Discoveries</span></a></li><li><a href="INDEX1F24.HTM?id=384" target="_self"><span>Books</span></a></li><li><a href="INDEX3958.HTM?id=467" target="_self"><span>Biographies</span></a></li><li><a href="INDEX677F.HTM?id=642" target="_self"><span>Perspectives</span></a></li><li><a href="INDEX8C00.HTM?id=343" target="_self"><span>Archives</span></a></li><li><a href="INDEX06CB.HTM?id=368" target="_self"><span>Ebooks</span></a></li><li><a href="INDEXA1F1.HTM?id=1755" target="_self"><span>Collated</span></a></li><li><a href="INDEXDF25.HTM?id=4128" target="_self"><span>Multilingual Project</span></a></li><li><a href="INDEXABE4.HTM?id=3884" target="_self"><span>INHN Publisher</span></a></li></ul></div></div>
		<div id="main">
			<div id="teaser" class="clearfix"><div class="rootline">You are here: <a href="INDEXAF9F.HTM?id=355" target="_self">Controversies</a>&nbsp;/&nbsp;Samuel Gershon: Device for naltrexone delivery</div><div class="langMenu"><div class="tx-srlanguagemenu-pi1">
		
	</div>
	</div></div>
			<div id="col1">
				<div id="col1_content" class="clearfix">
					<ul id="submenu"><li id="title">Controversies</li><li><a href="INDEX01FF.HTM?id=3395" target="_self">Jay D. Amsterdam and Leemon B. McHenry: The Paroxetine 352 Bipolar Study Revisited: Deconstruction of Corporate and Academic Misconduct.</a><span class="hidden">.</span></li><li><a href="INDEXC230.HTM?id=486" target="_self">Thomas A. Ban: Conflict of interest in neuropsychopharmacology</a><span class="hidden">.</span></li><li><a href="INDEX2AF5.HTM?id=1342" target="_self">Thomas A. Ban: Development of our Vocabulary</a></li><li><a href="INDEX1BE7.HTM?id=3220" target="_self">Thomas A. Ban:  Education in Biological Psychiatry – Homage to Dr. Heinz E. Lehmann</a></li><li><a href="INDEXFB00.HTM?id=829" target="_self">Barry Blackwell: Adumbration; A history lesson</a><span class="hidden">.</span></li><li><a href="INDEX7196.HTM?id=3970" target="_self">Barry Blackwell: A Tale of Two Pioneers.</a></li><li><a href="INDEXD39F.HTM?id=1665" target="_self">Barry Blackwell: Corporate Corruption in the Psychopharmaceutical Industry</a><span class="hidden">.</span></li><li><a href="INDEXF833.HTM?id=1944" target="_self">Barry Blackwell: Corporate Corruption in the Psychopharmaceutical Industry. Revised</a><span class="hidden">.</span></li><li><a href="INDEX8B56.HTM?id=778" target="_self">Barry Blackwell: The anxiety enigma</a><span class="hidden">.</span></li><li><a href="INDEX8B7A.HTM?id=2096" target="_self">Barry Blackwell: The Baby and The Bath Water</a><span class="hidden">.</span></li><li><a href="INDEX07C2.HTM?id=622" target="_self">Barry Blackwell: The lithium controversy: A historical autopsy</a><span class="hidden">.</span></li><li><a href="INDEX12D3.HTM?id=1369" target="_self">Pierre Baumann and Francois Ferrero: An official inqury of the clinical research activities (1946-1972) of Roland Kuhn (1912-2005)</a><span class="hidden">.</span></li><li><a href="INDEXA7C8.HTM?id=2954" target="_self">John Court: A note on the history of Anorexia Nervosa</a></li><li><a href="INDEX32F0.HTM?id=421" target="_self">Paul Devenyi: Addictions are not treatable diseases</a><span class="hidden">.</span></li><li><a href="INDEXE29D.HTM?id=477" target="_self">Paul Devenyi: Pharmacotherapy of addictions</a></li><li><a href="INDEXC591.HTM?id=3315" target="_self">Camille Drach Hojaij: Stein and Empathic Fulfilment.</a><span class="hidden">.</span></li><li><a href="INDEX3CB5.HTM?id=2526" target="_self">François Ferrero: Inquiry of the Geneva 1980s’ Psychiatry Crisis</a><span class="hidden">.</span></li><li><a href="INDEXC947.HTM?id=3727" target="_self">Max Fink: Reconceptualization of Catatonia.</a><span class="hidden">.</span></li><li><a href="INDEX3D6D.HTM?id=2322" target="_self">Ernst J. Franzek: From the dichotomy to a three-part grouping of endogenous psychoses</a><span class="hidden">.</span></li><li><a href="INDEX031F.HTM?id=3472" target="_self">Samuel Gershon: Brintellix  -  votioxetine</a></li><li><strong>Samuel Gershon: Device for naltrexone delivery</strong></li><li><a href="INDEX8E42.HTM?id=3064" target="_self">Samuel Gershon: Ketamine, the “new” breakthrough in the treatment of depression</a><span class="hidden">.</span></li><li><a href="INDEX1823.HTM?id=2488" target="_self">Samuel Gershon: Lithium history</a><span class="hidden">.</span></li><li><a href="INDEX5D83.HTM?id=3646" target="_self">Samuel Gershon: The emergence of “new” drugs in recent years.</a></li><li><a href="INDEXFA6F.HTM?id=3375" target="_self">Samuel Gershon: The Tacrine paradigm.</a><span class="hidden">.</span></li><li><a href="INDEXF3E3.HTM?id=670" target="_self">Samuel Gershon: The trazodone cntrovery and its potential fatal consequences</a></li><li><a href="INDEX4A93.HTM?id=2894" target="_self">Ken Gillman: Medical science publishing: A slow-motion train wreck</a><span class="hidden">.</span></li><li><a href="INDEXDBE8.HTM?id=3720" target="_self">David Healy: Do Randomized Controlled Trials Add to or Subtract from Clinical Knowledge?</a><span class="hidden">.</span></li><li><a href="INDEX3202.HTM?id=1350" target="_self">David Healy: The shipwreck of the singular</a><span class="hidden">.</span></li><li><a href="INDEX2555.HTM?id=2447" target="_self">Hanfried Helmchen: The role of psychopharmacotherapy in the early development of social psychiatry in Germany</a><span class="hidden">.</span></li><li><a href="INDEXE41A.HTM?id=2095" target="_self">Carlos R. Hojaij: A Psychopathological Marker For Biological Psychiatry:  The Point of No Return and the “Something New&quot; *</a></li><li><a href="INDEX4C30.HTM?id=1823" target="_self">Carlos R. Hojaij: “DSM-5: The Future of Psychiatric Diagnosis” or Continuing the Psychiatry DiSMantlement</a><span class="hidden">.</span></li><li><a href="INDEX14F7.HTM?id=2103" target="_self">Carlos R. Hojaij: Psychiatry and Medicine</a></li><li><a href="INDEX711C.HTM?id=2118" target="_self">Carlos R. Hojaij: Towards a Psychiatric Biology</a></li><li><a href="INDEX61B8.HTM?id=3147" target="_self">David Janowsky: Cholinergic muscarinic mechanisms in depression and mania</a><span class="hidden">.</span></li><li><a href="INDEXC12C.HTM?id=3956" target="_self">Daniel Kanofsky and Mary E. Woesner: A Fresh Air Approach to COVID-19.</a><span class="hidden">.</span></li><li><a href="INDEX0B8F.HTM?id=530" target="_self">Martin M. Katz: Component-Specific vs. Diagnosis-Specific Clinical Trial in Depression</a><span class="hidden">.</span></li><li><a href="INDEXBDA3.HTM?id=594" target="_self">Martin M. Katz: Multivantaged vs. conventional assessment method</a><span class="hidden">.</span></li><li><a href="INDEX46C5.HTM?id=496" target="_self">Martin M. Katz: Onset of clinical action of antidepressants</a><span class="hidden">.</span></li><li><a href="INDEX94E9.HTM?id=1147" target="_self">Martin  M. Katz: The need and rationale for shortenng the clinical trial for antidepressants</a></li><li><a href="INDEXB724.HTM?id=2329" target="_self">Donald F. Klein, Max Fink, Edward Shorter and Thomas A. Ban: Comment exchange on Flagrant Catatonic Behavior.</a><span class="hidden">.</span></li><li><a href="INDEXA16A.HTM?id=1625" target="_self">Joseph Knoll: Controversies on selegiline/(-)-deprenyl’s  pharmacological spectrum after more than 50 years of its development</a></li><li><a href="INDEX98B4.HTM?id=2771" target="_self">Magda Malewska-Kasprzak, Agnieszka Permoda-Osip, Janusz Rybakowski:Disturbances of the purinergic system in affective disorders and schizophrenia</a><span class="hidden">.</span></li><li><a href="INDEXBB29.HTM?id=4134" target="_self">Trudo Lemmens. “Medical Assistance in Dying” (Euthanasia and Assisted Suicide) in Canada: A Case Raises Questions About Its Use in Patients with Disability and Mental Illness.</a><span class="hidden">.</span></li><li><a href="INDEXEBA9.HTM?id=3891" target="_self">Amy S. F. Lutz: The Rise and Fall of the Dexamethasone Suppression Test: Stability, Consensus, Closure.</a><span class="hidden">.</span></li><li><a href="INDEX41D4.HTM?id=3252" target="_self">Gin S. Malhi: A critical analysis of concepts in psychiatry</a><span class="hidden">.</span></li><li><a href="INDEXD25B.HTM?id=2701" target="_self">Antonio E. Nardi, Richard Balon, Guy Chouinard, Fiammetta Cosci, Steven Dubovsky, Giovanni A. Fava, Rafael C. Freire, David J. Greenblatt, John H. Krystal, Karl Rickels, Thomas Roth, Carl Salzman, Richard I. Shader, Edward K. Silberman, Nicoletta Sonino,</a><span class="hidden">.</span></li><li><a href="INDEX4CFC.HTM?id=2972" target="_self">János Radó: Renal Toxicity of Lithium in Historical Perspective with Special Reference To Nephrogenic Diabetes Insipidus and its Treatment</a><span class="hidden">.</span></li><li><a href="INDEXD26F.HTM?id=3140" target="_self">Janos Radó: Desmopressin may counteract polyuria in lithium-induced nephrogenic diabetes insipidus. Review of the literature</a><span class="hidden">.</span></li><li><a href="INDEX13F5.HTM?id=1248" target="_self">Shridhar Sharma: Insulin coma treatment: Facts and controversies</a><span class="hidden">.</span></li><li><a href="INDEX5461.HTM?id=390" target="_self">Edward Shorter: The Q-T interval and the Mellaril story - a cautionary tale</a><span class="hidden">.</span></li><li><a href="INDEX70B9.HTM?id=2755" target="_self">Leonardo Tondo: Brief History of Suicide in Western Cultures</a><span class="hidden">.</span></li><li><a href="INDEX7938.HTM?id=2000" target="_self">Hector Warnes: The gut-brain axis</a><span class="hidden">.</span></li><li><a href="INDEXEABE.HTM?id=3450" target="_self">Hector Warnes: Pyridoxine in the treatment of lithium-induced tremor.</a><span class="hidden">.</span></li></ul>
					
					<div class="textBelowMenu"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
				</div>
			</div>
			<div id="col2">
				<div id="col2_content" class="clearfix"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
			</div>
			<div id="col3">
			  <a id="content" name="content"></a>
				<div id="col3_content" class="clearfix">
					<div class="floatbox"><!--TYPO3SEARCH_begin--><div id="c4995" class="csc-default"><h1>Samuel Gershon: Device for naltrexone delivery</h1>
<p>&nbsp;</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is a current (June 6, 2019) New York Times report from Australia about Dr. George O’Neal on his invention of an implant that can provide daily doses of naltrexone to subjects for about six months. Dr. O’Neal concludes in the article that his patients must fulfill a number of requirements before he will proceed to implant naltrexone:</p>
<p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; They must understand the entire treatment plan and comply with all requirements </p>
<p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; They must enter and complete a drug withdrawal treatment program</p>
<p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; They must enter a rehabilitation program and complete it satisfactorily and then&nbsp; he will proceed to implant the device to provide a six-month supply of naltrexone</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; So, these requirements needed to fulfill eligibility make evaluation of outcome more difficult.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The article went on to say that NIH will fund naltrexone implantation studies at Columbia University - $6.8 million for two years with a possibility of an additional $13 plus million.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, the experts in the discussion may wish to consider whether this device could contribute any answers to their discussion. One wonders whether such a device would offer advantages in using naltrexone in treatment. </p>
<p>&nbsp;</p>
<p>October 17, 2019</p></div><!--TYPO3SEARCH_end--></div>
				</div>
				<div id="ie_clearing">&nbsp;</div>
			</div>
		</div>
		<div id="footer">&copy; INHN 2012-2022 ::: INHN Central Office  · Av. Sagrada Familia Esq Nazaret · Córdoba, Córdoba X5000 · Argentina  ::: email: inhn@inhn.org</div>
	</div>
</div>





<script src="IMAGES/URCHIN.JS" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-39727086-1";
urchinTracker();
</script>
</body>
</html>